Use of colony-stimulating factors in the elderly cancer patient

Oncology Spectrums

Volumn 2, Issue 6, 2001, Pages 414-421

  Lyman, G H ^a   Balducci, L ^a   Agboola, Y ^a  

^a ALBANY MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; COLONY STIMULATING FACTOR; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEMOPOIETIC GROWTH FACTOR; MITOXANTRONE; PREDNIMUSTINE; PREDNISONE; VINBLASTINE; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; AGED; AGING; ARTICLE; BONE MARROW; BONE MARROW SUPPRESSION; CANCER; CANCER PATIENT; CHEMOPROPHYLAXIS; CLINICAL PRACTICE; COST CONTROL; DRUG TOLERABILITY; DRUG USE; HUMAN; LEUKEMIA REMISSION; NEUTROPENIA; NONHODGKIN LYMPHOMA; PRACTICE GUIDELINE; QUALITY OF LIFE; RISK;

EID: 0034883563     PISSN: 15328554     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Essentials of clinical decision analysis: A new way to think about cancer and age
2. Cancer care in the elderly: Cost and quality of life considerations
3. Aging and haemopoiesis. Implications for treatment with haemopoietic growth factors
4. Reduction in the incidence of chemotherapy-induced febrile neutropenia in patients with small cell lung cancer
5. Meta-analysis of granulocyte colony-stimulating factor to prevent febrile neutropenia in patients receiving cancer chemotherapy
6. Evidence for a continuous decline in hemopoietic cell function from birth: Application to evaluating bone marrow failure in children
7. Co-morbidity and functional status are independent in older cancer patients
8. Hemopoietic reserve in the older cancer patient: Clinical and economic considerations
9. Randomized trial with or without granulocyte colony-stimulating factor as adjunct to induction VNCOP-b treatment of elderly high-grade non-Hodgkin's lymphoma
10. Elderly patients with aggressive non-Hodgkin's lymphoma treated with CHOP chemotherapy plus granulocyte-macrophage colony-stimulating factor: Identification of two age subgroups with differing hematologic toxicity
11. CHOP is the standard regimen in patients ≥ 70 years of age with intermediate-grade and high-grade non-Hodgkin's lymphoma: Results of a randomized study of the European Organization for Research and Treatment Cooperative Study Group
12. Elderly patients with aggressive non-Hodgkin's lymphoma: Disease presentation, response to treatment, and survival-A Groupe d'Etude des Lymphomes de l'Adulte Study on 453 patients older than 69 years
13. In search of an optimal regimen for elderly patients with advanced-stage diffuse large-cell lymphoma: Results of a phase II study of P/DOCE chemotherapy
14. Randomized trial of R-methu granulocyte colony stimulating factors as adjunct to CHOP or CNOP treatment of elderly patients with aggressive non-Hodgkin's lymphoma
15. The treatment of elderly patients with aggressive non-Hodgkin's lymphomas: Feasibility and efficacy of an intensive multidrug regimen
16. Aggressive chemotherapy for diffuse histiocytic lymphoma in the elderly
17. Suboptimal dosing in adjuvant breast cancer chemotherapy: Evidence from a nationwide survey
18. Colony-stimulating factors may reduce complications and death in solid tumor patients with fever and neutropenia
19. Cost-benefit of granulocyte colony-stimulating factor administration in older patients with non-Hodgkin's lymphoma treated with combination chemotherapy
20. Prophylactic filgrastim (g-csf) during mitomycin-c, mitoxantrone, and methotrexate (MMM) treatment for metastatic breast cancer
21. Erythropoietin addition to granulocyte colony-stimulating factor abrogates life-threatening neutropenia and increases peripheral-blood progenitor-cell mobilization after epirubicin, paclitaxel and cisplatin Results of a randomized comparison
22. Randomized placebo-controlled phase III study of granulocyte-macrophage colony stimulating factor in adult patients > 55-70 years with acute myelogenous leukemia: A study of the Eastern Cooperative Oncology Group (E1490)
23. GM-CSF in a double-blind randomized, placebo controlled trial in therapy of adult patients with de novo acute myeloid leukemia (AML)
24. Use of recombinant GM-CSF during and after remission-induction chemotherapy in patients aged 61 and older with acute non-lymphocytic leukemia: Final report of AML-11, a phase III randomized study of the European Organization for the Research and Treatment of Cancer and the Dutch Belgian Hematology Oncology Cooperative Group
25. A placebo-controlled study of recombinant human granulocyte macrophage colony-stimulating factor administered during an induction treatment for "de novo" acute myelogenous leukemia in older patients
26. Granulocyte-macrophage colony stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia
27. A double-blind placebo-controlled trial of granulocyte colony-stimulating factor for elderly patients with previously untreated acute myelogenous leukemia: A Southwest Oncology Group Study
28. Granulocyte colony-stimulating factor following chemotherapy in elderly patients with newly diagnosed acute myelogenous leukemia
29. A controlled study of recombinant human granulocyte colony-stimulating factor in elderly patients after treatment for acute myelogenous leukemia
30. Decision analysis of hematopoietic growth factor use in patients receiving cancer chemotherapy
31. A cost analysis of hematopoietic colony-stimulating factors
32. The economics of febrile neutropenia: Implications for the use of colony-stimulating factors
33. Granulopoiesis stimulating agents: Economic impact on the management of febrile neutropenia
34. Economic analyses of the use of the colony-stimulating factors: An update
35. 2000 update of recommendations for the use of hematopoietic colony-stimulating factors: Evidence-based, clinical practice guidelines
36. Patients aged > or = 70 are at high risk for neutropenic infection and should receive hemopoietic growth factors when treated with moderately toxic chemotherapy
37. Impact of outpatient treatment of febrile neutropenia (FN) on risk thresholds for G-CSF prophylaxis in cancer chemotherapy (CT)